TIDMIMM

RNS Number : 0027Q

Immupharma PLC

16 June 2020

RNS | eCorporate 16 June 2020

ImmuPharma PLC

("ImmuPharma" or the "Company")

Total Share Capital Notification

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting rights are set out below:

 
 Situation as at 16 June 2020 
 
   1. Information to be provided for on the basis 
   of Article 15, --1, al. 1 
 Total of share capital (nominal value)                        :    GBP 18,301,092 
 
 Total number of shares with existing voting 
  rights (= denominator) - one vote per share                  :       183,010,920 
 
 2. Additional information to be provided on 
  the basis of Article 15, --1, al. 2 
 
  In respect to the announcement on 11 June 
  2020: "Investment from two specialist US healthcare 
  investors" 
 
            Convertible Securities (in whole or in part) 
             into ordinary shares. 
             The total conversion would result in an equal 
             number of voting rights                           :        13,086,619 
 
            Share options (in whole or in part) 
             The exercise of the options would result in 
             the creation of an equal number of ordinary 
             shares and voting rights.                         :        15,703,942 
 In respect to the announcement on 30 March 
  2020: "Subscription to raise GBP1.5m" 
 
            Warrants over ordinary shares (in whole or 
             in part) 
             The exercise of the warrants would result 
             in the creation of an equal number of ordinary 
             shares and voting rights                          :           915,205 
 
 Other outstanding rights to subscribe ordinary 
  shares as detailed in the Annual Report 2019 
  (Report and consolidated financial Statements 
  for the year ended 31 December 2019) 
 
            Share options (in whole or in part) 
             The exercise of the options would result in 
             the creation of an equal number of ordinary 
             shares and voting rights                          :        16,368,850

This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.

 
 
   For further information please contact: 
    ImmuPharma PLC ( www.immupharma.com ) 
     Tim McCarthy, Chairman                        + 44 (0) 207 152 4080 
    Dimitri Dimitriou, Chief Executive Officer 
    Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
    SPARK Advisory Partners Limited (NOMAD) 
     Neil Baldwin                                  +44 (0) 20 3 36 8 3550 
 
     Stanford Capital Partners (Joint Broker) 
     Patrick Claridge, John Howes                   +44 (0) 203 815 8880 
 
     SI Capital (Joint Broker) 
     Nick Emerson                                   +44 (0) 1483 413500 
    4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
     Jean-Charles Snoy 
 
     Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
     Erik De Clippel 
 
     Backstage Communication 
     Olivier Duquaine                               +32 (0) 477 504 784 
     Gunther De Backer                              +32 (0) 475 903 909

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase III trial for Lupuzor(TM) and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com . ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBXGDLGSBDGGU

(END) Dow Jones Newswires

June 16, 2020 02:00 ET (06:00 GMT)

Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Immupharma.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Immupharma.